RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

Lapatinib adds to the efficacy of trastuzumab in preclinical models and also in the neo-adjuvant setting. This study assesses the safety and feasibility of adding lapatinib to paclitaxel and trastuzumab (THL) as part of the adjuvant therapy for HER2-positive breast cancer (HER2+ BC). In this single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Aspitia, Alvaro, Dueck, Amylou C., Ghanem-Cañete, Ismael, Patel, Tejal, Dakhil, Shaker, Johnson, David, Franco, Sandra, Kahanic, Stephen, Colon-Otero, Gerardo, Tenner, Kathleen S., Rodeheffer, Richard, McCullough, Ann E., Jenkins, Robert B., Palmieri, Frances M., Northfelt, Donald, Perez, Edith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608861/
https://www.ncbi.nlm.nih.gov/pubmed/23479422
http://dx.doi.org/10.1007/s10549-013-2469-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608861/
https://www.ncbi.nlm.nih.gov/pubmed/23479422
http://dx.doi.org/10.1007/s10549-013-2469-2

Ejemplares similares